以PPAR为靶标的抗2型糖尿病药物研发策略  

Current strategies in research of anti-diabetics by employment of PPAR (peroxisome proliferator-activated receptor) as a target

作　　者：廖晨钟[1] 邓沱[1] 山松 潘德思 李志斌 宁志强 胡伟明 石乐明 周家驹[2] 鲁先平 

机构地区：[1]深圳微芯生物科技有限公司,深圳518057 [2]中国科学院过程工程研究所计算机化学实验室,北京100080

出　　处：《中国新药杂志》2003年第12期980-983,共4页Chinese Journal of New Drugs

基　　金：十五国家重大科技专项"创新药物与中药现代化"资助项目(No.2002AA2Z3146);3项国家863资助项目(No.2002AA234041;2002AA234021;2002AA104270);广东省2002年重大项目招标中标项目(No.2002-108)。

摘　　要：近年来发现2型糖尿病与过氧化物酶增殖体活化受体(peroxisome proliferator-activated receptor,PPAR)存在着密切的联系,该受体也因此成为设计抗2型糖尿病药物的主要靶标。目前,有很多针对PPAR所设计的化合物处于临床研究阶段,现介绍这方面的进展,并阐述开发抗2型糖尿病药物所面临的困难及相应的策略。It is found recently that close relationship existed between non-insulin dependent diabetes mellitus (NIDDM) and PPAR. Therefore, PPAR is now employed as a main target in developing anti-diabetics for treatment of NIDDM. Lately a lot of new chemical entities for treatment of NIDDM using PPAR as target at clinical trials have been developed. In this paper, progress in this aspect, and difficulties faced by developing anti-diabetics and their solutions are reviewed by the authors.

关 键 词：2型糖尿病 抗糖尿病药物 过氧化物酶增殖体活化受体(PPAR) 胰岛素增敏剂 

分 类 号：R977.1[医药卫生—药品] R587[医药卫生—药学]